143 related articles for article (PubMed ID: 26634172)
1. Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences.
Blanco R; Domínguez E; Morales O; Blanco D; Martínez D; Rengifo CE; Viada C; Cedeño M; Rengifo E; Carr A
Patholog Res Int; 2015; 2015():132326. PubMed ID: 26634172
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of N-glycolyl GM3 ganglioside is associated with the aggressive biological behavior of human sarcomas.
Pilco-Janeta D; De la Cruz Puebla M; Soriano J; Osorio M; Caballero I; Pérez AC; Savon L; Cremades N; Blanco R; Carr A
BMC Cancer; 2019 Jun; 19(1):556. PubMed ID: 31182063
[TBL] [Abstract][Full Text] [Related]
3. Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Epithelial Malignant Tumors from Digestive System.
Blanco R; Rengifo E; Cedeño M; Rengifo CE; Alonso DF; Carr A
ISRN Gastroenterol; 2011; 2011():645641. PubMed ID: 21991524
[TBL] [Abstract][Full Text] [Related]
4. Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Primary Lymphoid Tumors and Lymph Node Metastasis.
Blanco R; Blanco D; Quintana Y; Escobar X; Rengifo CE; Osorio M; Gutiérrez Z; Lamadrid J; Cedeño M; Frómeta M; Carr A; Rengifo E
Patholog Res Int; 2013; 2013():920972. PubMed ID: 24381785
[TBL] [Abstract][Full Text] [Related]
5. Immunoreactivity of the 14F7 Mab (Raised against N-Glycolyl GM3 Ganglioside) as a Positive Prognostic Factor in Non-Small-Cell Lung Cancer.
Blanco R; Rengifo CE; Cedeño M; Frómeta M; Rengifo E; Carr A
Patholog Res Int; 2012; 2012():235418. PubMed ID: 22482082
[TBL] [Abstract][Full Text] [Related]
6. N-Glycolyl GM3 ganglioside immunoexpression in oral mucosal melanomas of Chinese.
Zhong Y; Wu Y; Li C; Tang J; Wang X; Ren G; Carr A; Pérez R; Guo W
Oral Dis; 2012 Nov; 18(8):741-7. PubMed ID: 22574836
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical Reactivity of the 14F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and Malignant Skin Neoplasms.
Blanco R; Rengifo E; Rengifo CE; Cedeño M; Frómeta M; Carr A
ISRN Dermatol; 2011; 2011():848909. PubMed ID: 22363862
[TBL] [Abstract][Full Text] [Related]
8. Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications.
Palomo AG; Santana RB; Pérez XE; Santana DB; Gabri MR; Monzon KL; Pérez AC
Clin Exp Metastasis; 2016 Oct; 33(7):717-25. PubMed ID: 27449755
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Role of 14F7 Mab Immunoreactivity against N-Glycolyl GM3 Ganglioside in Colon Cancer.
Lahera T; Calvo A; Torres G; Rengifo CE; Quintero S; Arango Mdel C; Danta D; Vázquez JM; Escobar X; Carr A
J Oncol; 2014; 2014():482301. PubMed ID: 24639871
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression in Patients Receiving Racotumomab Immunotherapy.
Uskent N; Ayla S; Molinas Mandel N; Ozkan M; Teomete M; Baloglu H; Aydıncer C; Yergok H; Dogan E; Berk B; Yazar A
J Oncol; 2020; 2020():1360431. PubMed ID: 32670370
[TBL] [Abstract][Full Text] [Related]
11. Tissue Reactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Tumors of Neuroectodermal, Mesodermal, and Epithelial Origin.
Blanco R; Quintana Y; Blanco D; Cedeño M; Rengifo CE; Frómeta M; Ríos M; Rengifo E; Carr A
J Biomark; 2013; 2013():602417. PubMed ID: 26317019
[TBL] [Abstract][Full Text] [Related]
12. Immunoreactivity of the 14F7 Mab raised against N-Glycolyl GM3 Ganglioside in retinoblastoma tumours.
Torbidoni AV; Scursoni A; Camarero S; Segatori V; Gabri M; Alonso D; Chantada G; de Dávila MT
Acta Ophthalmol; 2015 Jun; 93(4):e294-300. PubMed ID: 25403557
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody.
Hernández AM; Toledo D; Martínez D; Griñán T; Brito V; Macías A; Alfonso S; Rondón T; Suárez E; Vázquez AM; Pérez R
J Immunol; 2008 Nov; 181(9):6625-34. PubMed ID: 18941253
[TBL] [Abstract][Full Text] [Related]
14. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
Wang X; Cao L; Li S; Wang F; Huang D; Jiang R
J Cancer; 2019; 10(26):6703-6710. PubMed ID: 31777599
[No Abstract] [Full Text] [Related]
15. Anti-NeuGcGM3 reactivity: a possible role of natural antibodies and B-1 cells in tumor immunosurveillance.
Rodriguez-Zhurbenko N; Rabade-Chediak M; Martinez D; Griñan T; Hernandez AM
Ann N Y Acad Sci; 2015 Dec; 1362():224-38. PubMed ID: 26214505
[TBL] [Abstract][Full Text] [Related]
16. Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer.
Gajdosik Z
Drugs Today (Barc); 2014 Apr; 50(4):301-7. PubMed ID: 24918647
[TBL] [Abstract][Full Text] [Related]
17. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients.
Alfonso S; Valdés-Zayas A; Santiesteban ER; Flores YI; Areces F; Hernández M; Viada CE; Mendoza IC; Guerra PP; García E; Ortiz RA; de la Torre AV; Cepeda M; Pérez K; Chong E; Hernández AM; Toledo D; González Z; Mazorra Z; Crombet T; Pérez R; Vázquez AM; Macías AE
Clin Cancer Res; 2014 Jul; 20(14):3660-71. PubMed ID: 24788102
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer.
Richardson CM; Richardson D; Swinson DE; Swain WA; Cox G; O'Byrne KJ
Lung Cancer; 2005 Apr; 48(1):47-57. PubMed ID: 15777970
[TBL] [Abstract][Full Text] [Related]
19. Human antibodies reactive to NeuGcGM3 ganglioside have cytotoxic antitumor properties.
Rodríguez-Zhurbenko N; Martínez D; Blanco R; Rondón T; Griñán T; Hernández AM
Eur J Immunol; 2013 Mar; 43(3):826-37. PubMed ID: 23319307
[TBL] [Abstract][Full Text] [Related]
20. Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism.
Hernández AM; Rodríguez N; González JE; Reyes E; Rondón T; Griñán T; Macías A; Alfonso S; Vázquez AM; Pérez R
J Immunol; 2011 Mar; 186(6):3735-44. PubMed ID: 21300821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
